SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 544 participants.

Also called NCT06442280

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 544 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06442280
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06442280. Randomized; single masking; primary purpose treatment. Start 2024-06 (anticipated); primary completion 2026-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
Acronym
DAPA-TONIC
Condition
Heart Failure Acute
Condition
Diabetes Type 2
Intervention (Drug)
Dapagliflozin tablet
Intervention (Drug)
Hypertonic Saline Solution, 1 Ml
Intervention (Drug)
Furosemide Injection
Lead sponsor
University of Palermo (class: other)

Record details

Record id
cardio:ct-nct06442280
Content hash
170fe74980b543d0a34b0d9774fd834f968e9d1e712742350cb1dce51c258d5a